Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
- Conditions
- Clinical Stage IVA Gastric Cancer AJCC v8Gastric AdenocarcinomaPostneoadjuvant Therapy Stage I Gastric Cancer AJCC v8Clinical Stage III Gastric Cancer AJCC v8Pathologic Stage IIIC Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8Pathologic Stage IB Gastric Cancer AJCC v8Pathologic Stage IIB Gastric Cancer AJCC v8Pathologic Stage IIIB Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04523818
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PRECISE CURATE.AI Pilot Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 20
- Registration Number
- NCT04522284
- Locations
- 🇸🇬
Ng Teng Fong General Hospital, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT04518280
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
🇨🇳Shanghai Changzheng Hospital, Shanghai, Shanghai, China
🇨🇳Zhen Zhang, Shanghai, Shanghai, China
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 460
- Registration Number
- NCT04501523
- Locations
- 🇨🇳
Sunyat-sen Memorial Hospital, Guandong, Guangdong, China
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 866
- Registration Number
- NCT04494425
- Locations
- 🇬🇧
Research Site, Northwood, United Kingdom
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT04495296
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Johannes Laengle, MD, PhD
- Target Recruit Count
- 1638
- Registration Number
- NCT04488159
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 54
- Registration Number
- NCT04464174
- Locations
- 🇪🇸
Hospital Quiron San Camilo- Ruber Juan Bravo, Madrid, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇵🇹Champalimaud Clinical Centre - Champalimaud Foundation, Lisboa, Portugal
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 335
- Registration Number
- NCT04456699
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias ( Site 1153), Oviedo, Asturias, Spain
🇺🇸Providence Portland Medical Center ( Site 1400), Portland, Oregon, United States
🇺🇸Oregon Health & Science University ( Site 1411), Portland, Oregon, United States
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Laura M. Spring, MD
- Target Recruit Count
- 120
- Registration Number
- NCT04443348
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.